ABSTRACT
Objective To analyze the efficacy and safety of erythropoietin combined with chalybeate in the treatment of perioperative anemia in patients with femoral intertrochanteric fracture.Methods A total of 112 patients with femoral intertrochanteric fracture who were treated by PFNA from May 2014 and May 2016 in our hospital were enrolled in this prospective study.They were divided into the treatment group (57 patients) and the control group (55 patients).The following data were recorded and compared:preoperative waiting time,operation time,intraoperative blood loss,number and volume needed blood transfusion at intraoperative and postoperative,the value of Hb and Hct on admission,before operation,1 st,3rd and 5th day after operation,the wound infection,pulmonary and urinary infection,deep vein thrombosis and plumonary embolism.Results There was no significant difference between the two groups in preoperative waiting time,operation time,intraoperative blood loss and perioperative blood loss (P ＜ 0.05).Treatment group has less patients (7％,4/57) in transfusion compared with control group (21％,12/55),and the difference was significant (P =0.01).There was no significant difference in the average volume of transfusion between the treatment group [(2.4 ±0.85)u] and the control group [(2.5 ±0.82)u].The value of Hb and Hct were most significantly decreased at the 3rd day after operation in both of the two groups,and they exceed the control group at the 3rd and 5th day after operation compared with the treatment group with significant difference(P ＜ 0.05).Treatment group has higher value of Hct at pre-and postoperative compared with that of the control group (P ＜ 0.01).There was no infection,deep vein thrombosis and plumonary embolism occurred in the to groups.Conclusion Erythropoietin combined with chalybeate in the treatment of perioperative anemia during femoral intertrochanteric fracture is a safe and effective method which can significantly reduce the rate of perioperative blood transfusion,while not increasing infection,deep vein thrombosis and plumonary embolism.